Comprehensive Financial Consultants Institutional Inc. Has $5.28 Million Stock Holdings in AbbVie Inc. $ABBV

Comprehensive Financial Consultants Institutional Inc. grew its position in shares of AbbVie Inc. (NYSE:ABBV) by 22.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 22,801 shares of the company’s stock after acquiring an additional 4,144 shares during the quarter. AbbVie accounts for 1.6% of Comprehensive Financial Consultants Institutional Inc.’s holdings, making the stock its 12th biggest position. Comprehensive Financial Consultants Institutional Inc.’s holdings in AbbVie were worth $5,279,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Conning Inc. increased its holdings in shares of AbbVie by 7.1% during the second quarter. Conning Inc. now owns 191,023 shares of the company’s stock worth $35,458,000 after purchasing an additional 12,690 shares during the period. Dohj LLC grew its position in AbbVie by 41.8% during the second quarter. Dohj LLC now owns 4,529 shares of the company’s stock worth $802,000 after buying an additional 1,335 shares in the last quarter. First Hawaiian Bank increased its stake in AbbVie by 0.8% during the 2nd quarter. First Hawaiian Bank now owns 7,556 shares of the company’s stock worth $1,403,000 after acquiring an additional 60 shares during the period. Charles Schwab Trust Co raised its holdings in AbbVie by 93.4% in the 3rd quarter. Charles Schwab Trust Co now owns 32,105 shares of the company’s stock valued at $7,434,000 after acquiring an additional 15,502 shares in the last quarter. Finally, World Investment Advisors lifted its position in shares of AbbVie by 9.4% during the 3rd quarter. World Investment Advisors now owns 113,925 shares of the company’s stock valued at $26,378,000 after acquiring an additional 9,811 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Price Performance

ABBV stock opened at $230.07 on Friday. The stock has a market cap of $406.63 billion, a price-to-earnings ratio of 174.30, a P/E/G ratio of 1.31 and a beta of 0.36. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60. The company has a 50 day simple moving average of $226.73 and a 200 day simple moving average of $212.57. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date of this dividend is Friday, January 16th. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is currently 496.97%.

Analyst Ratings Changes

A number of research firms recently commented on ABBV. Wells Fargo & Company boosted their price target on AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. JPMorgan Chase & Co. boosted their target price on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and upped their price target for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Hsbc Global Res raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, December 10th. Finally, Morgan Stanley upped their target price on AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $245.84.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.